Abstract 327P
Background
Sentinel lymph node biopsy (SLNB) has been widely used to assess axillary staging. In clinical practice, it is crucial to define sentinel lymph node (SLN) and determine whether the detected nodes are SLNs during the process of SLNB. It is important to consider whether currently existing consensus on SLNB method which is dual-tracer technique may lead to the excessive and unnecessary removal of negative nodes. In addition, no uniform measurable and objective index has been established to define intra-operation palpable nodes, the excision of which may increase the random detection of SLN. The purpose of this study was to optimize the specific method of SLNB.
Methods
To propose an optimal cut-off value for “radioisotope+bule dye” dual-tracer method, the detailed information of (BC) patients who had no clinical node involvement and underwent SLNB from November 2010 to February 2021 was prospectively collected in the breast surgery department of West China Hospital. We analyzed the site and size, radioactivity, the status of blue dye and the pathological results of each node detected of each patients.
Results
A total of 4985 lymph nodes from 1595 BC patients were identified. Only 11.57% (577/4985) SLNs were defined as pathologically positive, resulting in 88.43% (4408/4985) negative nodes removed excessively. By gradually increasing the threshold of radioisotope count in comparison to the hottest SLN, we found that when elevating the cut-off value from 10% to approximately 60%, 17.3% of lymph nodes were spared removal, among which only 0.88% were missed positive SLNs. Raising the optimal cutoff value of radioisotopes to 60% and exempting palpable nodes at the same time could reduce the number of nodes detected by 30.81% with only 1.75% missed positive SLNs. Additionally, multivariate analysis in our study showed that larger tumor size and higher clinical N stage was significantly positively associated with SLN metastasis.
Conclusions
Raising the optimal cut-off value of radioisotope to 60% and exempting palpable nodes may be considered as a potential alternative method to avoid removing excessive negative nodes in SLNB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q. Lv.
Funding
West China Hospital, Sichuan University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
272P - Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict & prevent project (P&P)
Presenter: Stefania Gori
Session: Poster session 02
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02